New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareHGH Fragment 176-191 vs Bronchogen

HGH Fragment 176-191 vs Bronchogen

Side-by-side comparison of key properties, dosing, and research.

Fat Loss & Metabolic
HGH Fragment 176-191
Anti-Aging & Longevity
Bronchogen
Summary
HGH Fragment 176-191 (also known as AOD-9604) is a stabilized, modified fragment of the human growth hormone molecule corresponding to amino acids 176–191 with an addition of a tyrosine residue at the N-terminus. It retains HGH's fat-burning properties without the anabolic, diabetogenic, or IGF-1-stimulating effects.
Bronchogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Leu) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is a tissue-specific bioregulator designed for the bronchi and lungs, promoting normalization of bronchial epithelial cell function. Research suggests benefits for respiratory health, protection against pulmonary aging, and support for bronchopulmonary conditions.
Half-Life
~30 minutes
Short (minutes to hours); bioregulator effects are gene-mediated and longer lasting
Admin Route
SubQ
SubQ, Oral
Research
Typical Dose
250–500 mcg
10 mg per day
Frequency
1–3 times daily
Daily for 10–30 days
Key Benefits
  • Selective fat burning without anabolic side effects
  • Reduces visceral and subcutaneous fat
  • No insulin resistance or blood glucose disruption
  • Does not stimulate IGF-1
  • May support cartilage and bone repair (at higher doses)
  • No effect on growth or organ size
  • Tissue-specific support for bronchial and lung health
  • Promotes normalization of bronchial epithelial cell function
  • Potential benefits in chronic bronchitis and COPD support
  • Anti-aging effects on pulmonary tissue
  • May reduce frequency of respiratory infections
  • Supports lung function preservation with aging
  • Compatible with other Khavinson bioregulator peptides
Side Effects
  • Injection site irritation
  • Temporary lethargy
  • Headache (rare)
  • Nausea (rare)
  • Generally well tolerated in research studies
  • Mild local reactions at injection site (if injected)
  • No significant systemic side effects reported at standard doses
Stacks With